Endpoints NewsOriginal article
Evommune's MRGPRX2 antagonist flunks its second I&I trial this summer
Phase 2negativeMRGPRX2 antagonistNegative
AI Analysis
Summary
Evommune's MRGPRX2 antagonist small molecule failed a Phase 2b trial in atopic dermatitis, marking the second mid-stage clinical failure for this Dermira-derived candidate this summer.
Clinical Trial Data
Phase
2b
Primary Endpoint
Not Met
Outcome Details
Phase 2b trial in atopic dermatitis failed; second mid-stage failure for the drug
Importance:6/10
Sentiment:
-0.90
clinical trial failurePhase 2batopic dermatitisMRGPRX2Evommune
Read the original article
Published by Endpoints News on September 9, 2026 7:38 AM